close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 +2.63 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
68 69 Next >
News headline image
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable. ↗
NASDAQ:VRTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic ↗
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function. 
Via Benzinga
News headline image
Got $500? 3 Pharma Stocks to Buy and Hold Forever ↗
These players might even beat the market when the conditions are right. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗
Shares of the growing biotech company have doubled in three years. 
Via The Motley Fool
News headline image
2 Biotech Stocks to Buy in May ↗
You could buy these in any month, really. 
Via The Motley Fool
News headline image
3 High-Flying Stocks That Could Soar Even More ↗
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. 
Via The Motley Fool
News headline image
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
Should you consider NASDAQ:VRTX for quality investing? ↗
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Exhibits Quality Stock Traits. Here's Why. 
Via Chartmill
News headline image
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
SLB, First Solar And 2 Other Stocks Insiders Are Selling ↗
 
Via Benzinga
News headline image
Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' ↗
Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents. 
Via Benzinga
News headline image
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now ↗
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. 
Via InvestorPlace
News headline image
Vertex to Participate in Upcoming June Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating ↗
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
News headline image
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics ↗
 
Via Benzinga
News headline image
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So. ↗
How much would you pay for a stock that might earn $25 a year in six years? 
Via The Motley Fool
News headline image
Jennifer Schneider Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades' ↗
Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform. 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating ↗
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
News headline image
3 Cheap Biotech Stocks to Buy Now: May 2024 ↗
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market. 
Via InvestorPlace
News headline image
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy ↗
The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors. 
Via The Motley Fool
News headline image
2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade ↗
These companies are raking in profits at astonishing clips. 
Via The Motley Fool
News headline image
Stock Market Moves Toward Highs; Arista, Toast, Palantir Key Earnings Movers: Weekly Review ↗
Big earnings winners and losers continued. 
Via Investor's Business Daily
News headline image
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. 
Via MarketBeat
Topics ETFs
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX. ↗
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable. 
Via Chartmill
News headline image
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip ↗
New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy now and hold over the long run. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Markets In A Minute - "A Lack Of Further Progress" ↗
May's FOMC meeting left the Fed Funds Rate unchanged. JOLTS showed fewer job openings with increased layoffs. April's job report disappointed, adding only 175k jobs and seeing higher unemployment.... 
Via Talk Markets
Topics Economy Workforce
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
US Stocks Eye Fourth Positive Session Despite Hawkish Fed Remarks; Disney, Palantir Tumble; Treasury Yields Fall: What's Driving Markets Tuesday? ↗
Wall Street experienced a quiet session during morning trading on Tuesday, influenced by a lack of significant economic data and minimal updates on earnings from major large-cap companies. 
Via Benzinga
Topics Economy
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today